[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"biofilm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:biofilm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100624331","effects-of-biocidin-on-oral-biofilms-100624331",false,"NCT07408245","Effects of Biocidin on Oral Biofilms","Prospective Human Study Evaluating the Effects of Biocidin Liquid on Oral Biofilms: An Open-label Pilot Study","Inclusion Criteria:\n\n1. Adult females or males age ≥ 25 years\n2. Ability to read and speak English\n3. Willingness to take use oral Biocidin as directed for two weeks\n4. Willingness not to change any other oral health practices for two weeks\n5. Willingness not to change dietary habits for two weeks\n6. Willingness to perform a SimplyPERIO oral microbiome test before and after the two-week Biocidin intervention\n\nExclusion Criteria:\n\n1. Current use of oral Biocidin or botanical mouthwash\n2. Use of antibiotics within the past 30 days\n3. Current use of fixed intraoral orthodontic appliances (e.g., dental braces, fixed retainers, or similar devices)\n4. Known allergies to any of the ingredients in the product\n5. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks\n6. Participants unable to provide consent",true,"ALL","25 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary purpose of this study is to evaluate the effects of Biocidin liquid on oral biofilms among healthy adults. A single-arm, open-label prospective study will be conducted evaluating the impact of two weeks of supplementation with label dosing of Biocidin liquid on oral biofilms as assessed by SimplyPERIO (Spectrum Solutions, Salt Lake City, UT).",[27],"Biofilm","RECRUITING","2026-03-09",{"date":31,"type":32},"2026-03-11","ACTUAL",{"date":34,"type":32},"2026-02-17",{"date":36,"type":21},"2026-04",{"name":38,"class":39},"OvationLab","NETWORK",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100623062","early-phase-1-efficacy-of-a-polyhexanide-biguanide-based-gel-in-the-prevention-of-biofilm-formation-in-pressure-ulcers-100623062","NCT07391748","Efficacy of a Polyhexanide Biguanide-Based Gel in the Prevention of Biofilm Formation in Pressure Ulcers","EGELPUPP","Inclusion Criteria:\n\n* Bedridden patients, patients with bed-to-chair mobility, or those in a wheelchair.\n* Presenting one or more category II-III pressure ulcers.\n* Aged over 65 years.\n* Patients with laboratory results within normal metabolic values (HbA1c \\\u003C 7%).\n* Patients who, in item 6 \"infection\u002Fsuspected biofilm\" of the RESVECH 2.0 index, do not have tissue compatible with biofilm, hypergranulation, or purulent exudate, and never score more than 4 in the other items.\n* During follow-up, cases that develop signs and symptoms of local infection according to TILI and\u002For the RESVECH 2.0 index will be considered therapeutic failures, allowing for clinical rescue, but the patient will remain in the intention-to-treat (ITT) analysis.\n\nExclusion Criteria:\n\n* Patients who, despite the above, present a deteriorated health status that could influence the outcome, such as terminally ill patients, oncology patients, or those with inflammatory diseases.\n* Patients in a state of malnutrition according to the Mini Nutritional Assessment (MNA®) scale who are not receiving nutritional supplements, and\u002For at risk of malnutrition with nutritional deficits.\n* Patients with pressure ulcers in the perineal area and urinary incontinence (except those with a urinary catheter) and\u002For fecal incontinence.","65 Years",{"count":50,"type":21},140,[52],"EARLY_PHASE1","INTRODUCTION: Pressure ulcers (PU) are one of the main challenges for nursing in our country. Wound bed preparation and the TIME algorithm provide essential tools for adequately treating these lesions. However, these wounds tend to become chronic due to the bacterial load in their bed. It is now known that bacteria can form complex and diverse structures, named as biofilm, which are difficult to diagnose and much more resistant to antimicrobial action.\n\nControlling these biofilms is crucial to create the optimal conditions for wound healing. Currently, it is believed that biofilms are present in 60-100% of chronic wounds. Therefore, more studies are needed to evaluate the efficacy of different antimicrobial agents on these structures.\n\nOBJECTIVE: To determine the efficacy of a gel containing polyhexanide and biguanide, alone or in combination with alginate with or without silver, in preventing biofilm in PU, in terms of healing at 4 weeks.\n\nMETHODOLOGY: Multicenter clinical trial with a 2x2 factorial design, conducted with patients from Alcoy with category II and III PUs that meet the inclusion and exclusion criteria. A sample of 140 participants is estimated, distributed into four groups of 35 patients. The interventions that will be carried out will be: application of Prontosan gel® and Aquacel Ag+®; Aquacel Ag+®; control group; Prontosan gel®. Data on wound evolution will be collected using RESVECH 2.0. Descriptive statistical analysis and hypothesis testing will be performed.",[55,56,57,58,59,27,60],"Pressure Ulcers","Pressure Ulcers Stage III","Pressure Ulcer Prevention","Pressure Ulcer ( Stage 2-3)","Biofilm Formation","Biofilm Removal",[62,63,64,65],"Pressure ulcers","biofilms","primary prevention","antimicrobial agents","NOT_YET_RECRUITING","2026-02-06",{"date":69,"type":32},"2026-02-10",{"date":71,"type":21},"2026-01-30",{"date":73,"type":21},"2026-09-30",{"name":75,"class":76},"Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana","OTHER"]